Fickert, Peter

CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice†

Wagner, M., Halilbasic, E., Marschall, H., Zollner, G., Fickert, P., Langner, C., Zatloukal, K., Denk, H., & Trauner, M. (2005) · Hepatology

Drug Transport and Resistance MechanismsPharmacogenetics and Drug Metabolism

Cited by 355

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H.-U., Altorjay, I., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., et al. (2017) · Journal of Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 297

Role of endoscopy in primary sclerosing cholangitis: European society of gastrointestinal endoscopy (ESGE) and European association for the study of the liver (EASL) clinical guideline

Aabakken, L., Karlsen, T., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J.-M., Färkkilä, M., Fickert, P., Hirschfield, G., Laghi, A., et al. (2017) · Endoscopy

Liver Diseases and ImmunityGallbladder and Bile Duct Disorders

Cited by 255

Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis

Baghdasaryan, A., Fuchs, C. D., Österreicher, C. H., Lemberger, U. J., Halilbasic, E., Påhlman, I., Graffner, H., Krones, E., Fickert, P., Wahlström, A., et al. (2016) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 187

Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts

Fickert, P., Fuchsbichler, A., Moustafa, T., Wagner, M., Zollner, G., Halilbasic, E., Stöger, U., Arrese, M., Pizarro, M., Solís, N., et al. (2009) · The American Journal of Pathology

Liver physiology and pathologyLiver Disease Diagnosis and Treatment

Cited by 169

Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis

Reich, M., Spomer, L., Klindt, C., Fuchs, K., Stindt, J., Deutschmann, K., Höhne, J., Liaskou, E., Hov, J. R., Karlsen, T. H., et al. (2021) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 121

Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline

Aabakken, L., Karlsen, T. H., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J.-M., Färkkilä, M., Fickert, P., Hirschfield, G. M., Laghi, A., et al. (2017) · Journal of Hepatology

Liver Diseases and ImmunityGallbladder and Bile Duct Disorders

Cited by 107

Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis

Horvath, A., Rainer, F., Bashir, M., Leber, B., Schmerboeck, B., Klymiuk, I., Groselj-Strele, A., Durdevic, M., Freedberg, D. E., Abrams, J. A., et al. (2019) · Scientific Reports

Gut microbiota and healthLiver Disease and Transplantation

Cited by 93

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial

Traussnigg, S., Schattenberg, J. M., Demir, M., Wiegand, J., Geier, A., Teuber, G., Hofmann, W. P., Kremer, A. E., Spreda, F., Kluwe, J., et al. (2019) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 88

Will we ever model PSC? – “It's hard to be a PSC model!”

Pollheimer, M. J., Trauner, M., & Fickert, P. (2011) · Clinics and Research in Hepatology and Gastroenterology

Liver Diseases and ImmunityLiver physiology and pathology

Cited by 66

Soluble CD 163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation

Rainer, F., Horvath, A., Sandahl, T. D., Leber, B., Schmerboeck, B., Blesl, A., Groselj‐Strele, A., Stauber, R. E., Fickert, P., Stiegler, P., et al. (2018) · Alimentary Pharmacology & Therapeutics

Liver Disease and TransplantationLiver physiology and pathology

Cited by 65

Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis

Pollheimer, M. J., Racedo, S., Mikels-Vigdal, A., Marshall, D., Bowlus, C., Lackner, C., Madl, T., Karlsen, T. H., Hov, J. R., Lyman, S. K., et al. (2018) · Journal of Hepatology

Liver Diseases and ImmunityLiver physiology and pathology

Cited by 38

Vitamin D modulates biliary fibrosis in ABCB4-deficient mice

Hochrath, K., Stokes, C. S., Geisel, J., Pollheimer, M. J., Fickert, P., Dooley, S., & Lammert, F. (2014) · Hepatology International

Liver Diseases and ImmunityLiver physiology and pathology

Cited by 36

Bile acids and glucocorticoid metabolism in health and disease

Theiler-Schwetz, V., Zaufel, A., Schlager, H., Obermayer-Pietsch, B., Fickert, P., & Zollner, G. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Adrenal Hormones and DisordersDrug Transport and Resistance Mechanisms

Cited by 31

Sulfasalazine reduces bile acid induced apoptosis in human hepatoma cells and perfused rat livers

Rust, C., Bauchmuller, K., Bernt, C., Vennegeerts, T., Fickert, P., Fuchsbichler, A., & Beuers, U. (2006) · Gut

Drug-Induced Hepatotoxicity and ProtectionDrug Transport and Resistance Mechanisms

Cited by 20